Related Experiment Video

Updated: Jun 11, 2026

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

ARRDC3 suppresses breast cancer progression by negatively regulating integrin beta4

K M Draheim1, H-B Chen, Q Tao

  • 1Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605, USA.

Oncogene
|July 7, 2010
PubMed

Insights

The arrestin-3 (ARRDC3) gene, often lost in breast cancer, inhibits tumor growth and spread by degrading the aggressive protein beta-4 integrin (ITGbeta4). This discovery reveals a new therapeutic target for breast cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Large-scale genetic analyses identify cancer-related genes, but their functions require further investigation.
  • The arrestin family member ARRDC3 is frequently lost in breast cancers, suggesting a tumor-suppressive role.

Purpose of the Study:

  • To investigate the cellular effects and molecular mechanism of ARRDC3 in breast cancer.
  • To explore the potential of the ARRDC3-ITGbeta4 pathway as a therapeutic target.

Main Methods:

  • Analysis of Oncomine data to correlate ARRDC3 expression with tumor characteristics.
  • Functional studies involving ARRDC3 overexpression and downregulation in cancer cells.
  • Mechanistic studies to elucidate the interaction between ARRDC3 and beta-4 integrin (ITGbeta4).

Main Results:

  • ARRDC3 expression inversely correlates with tumor grade, metastasis, and recurrence.
  • ARRDC3 overexpression suppresses cancer cell proliferation, migration, invasion, anchorage-independent growth, and tumorigenicity.
  • ARRDC3 directly binds to phosphorylated ITGbeta4, leading to its internalization, ubiquitination, and degradation.

Conclusions:

  • ARRDC3 acts as a tumor suppressor in breast cancer by regulating ITGbeta4.
  • The ARRDC3-ITGbeta4 pathway represents a novel therapeutic target for breast cancer.
  • Integrating genetic data with mechanistic studies is crucial for developing new cancer treatments.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Related Concept Videos

Activation of Integrins01:15

Activation of Integrins

Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Integrins01:10

Integrins

Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.